Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is about allergic diseases in people living in Mali. Allergic diseases can cause health problems like asthma or skin rashes. In this study, the investigators will look for clues about things that may affect whether people get allergic diseases. The investigators will look at things on or in the body, like germs, and things in the environment, like pollution. To do this, the investigators will collect different types of biological samples, health information, and environmental information from people with allergic diseases and people without allergic diseases. The investigators will compare what is found in each group to look for differences that might be related to allergic disease.
This is a case-control study where participants from Bamako in Mali will be screened to identify patients with atopic disease (asthma and atopic dermatitis). Age and sex-matched healthy controls will be selected at a 1:1 ratio. All study participants (including healthy controls) will undergo a clinical evaluation and provide skin swabs, nasal swabs, induced sputum (if successful), blood samples, drinking water samples, stool samples, as well as complete an interviewer-administered questionnaire on environmental exposures. All participants (including healthy controls) will also undergo pulmonary function testing (spirometry and/or oscillometry) and undergo testing of transepidermal electrical impedance (using a Nevisense machine). Samples will be used to evaluate the microbiome diversity in participants with allergy-related diseases (ARDs) compared to healthy controls. Environmental surveys will assess the association between atopy and exposures that are primarily outdoor versus indoor exposures. Temporal and spatial variation in these pollutants will be assessed. Air samples taken from the community and participant home drinking water samples (when available) will be used to assess the presence and variability of pollutants in the environment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants with atopic disease (asthma or atopic dermatitis) | |||
| Age/sex-matched healthy volunteers. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Differences in gut microbiome between atopic patients and healthy controls in children and adults. | Shannon diversity index analyzed using t-test with significance level of .05, will be lower in patients with atopic disease. | Within 28 days after the screening visit. |
| Measure | Description | Time Frame |
|---|---|---|
| Relative abundance of taxa and expression of metabolically functional genes in the skin microbiome. | RNAseq | Within 28 days after the screening visit. |
| Relative abundance of taxa and expression of metabolically functional genes in the gut microbiome. |
Not provided
Inclusion Criteria (Study Group):
Inclusion Criteria (Healthy Volunteers):
Exclusion Criteria:
Not provided
Not provided
Not provided
Study participants will be recruited from the Bamako area
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Cisse Lamissa, MD | Contact | +223 66956944 | lamissa05@gmail.com | |
| Khadida Ouattara, MD, MSc | Contact | +223 66780357 | zankhadi@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Ian Myles, MD | NIAID, National Institutes of Health (NIH) | Principal Investigator |
| Kingsley Osei-Karikari | National Institutes of Health (NIH) | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dermatology Hospital of Bamako | Recruiting | Bamako | Mali |
Not provided
| ID | Term |
|---|---|
| D001249 | Asthma |
| D003876 | Dermatitis, Atopic |
| D006967 | Hypersensitivity |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Skin swabs, nasal swabs, sputum, whole blood, stool, urine, skin tape strip
Metagenomic sequencing
| Within 28 days after the screening visit. |
| Relative abundance of taxa and expression of metabolically functional genes in the nasal microbiome | Metagenomic sequencing | Within 28 days after the screening visit. |
| Presence, frequency, and/or proximity to environmental exposures. | Patient survey to establish risk. Higher exposure, linked to higher atopy risk. | Within 28 days after the screening visit. |
| Serum concentration of total IgE, specific IgE panels, and eosinophils | Within 28 days after the screening visit. |
| Concentration of pollutants or pollutant biomarkers in urine and serum | Within 28 days after the screening visit. |
| Pneumology Ward, Point G University Hospital | Recruiting | Bamako | Mali |
|
| D012130 |
| Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D007154 | Immune System Diseases |
| D012873 | Skin Diseases, Genetic |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D003872 | Dermatitis |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D017443 | Skin Diseases, Eczematous |